Nov 20, 04:41 PM

Grifols Faces Brookfield's €6.5 Billion Bid at €10.50 per Share Amid 82% Analyst Skepticism

Grifols, a Spanish pharmaceutical company, is facing challenges regarding a potential takeover by Brookfield. The latter's offer values Grifols at €6.5 billion, or €10.50 per share. However, Grifols' Transaction Committee has deemed this valuation insufficient. In support of Brookfield's bid, Temasek and GIC have pledged €3 billion. Despite this backing, analysts remain skeptical, with 82% valuing Grifols above the proposed price. Recent trading saw Grifols' shares rise by 1.21% to €10.46, reflecting market uncertainty about the offer. Additionally, the Audiencia Nacional is set to investigate reports related to Grifols, further complicating the situation as Brookfield's bid appears to be cooling.

#Grifols #Spanish #Brookfield #Temasek #GIC #Audiencia Nacional

Written with ChatGPT (GPT-4o mini).

Sources

CincoDiascom@CincoDiascom
2 years ago
Las acciones de Grifols han subido este miércoles un 1,21%, hasta 10,46 euros, si bien durante la jornada han llegado a cotizar en 10,50 euros, precio que maneja Brookfield en su posible opa sobre la compañía. La propuesta del fondo se realiza junto a miembros de la familia…
elEconomista.es@elEconomistaes
2 years ago
El 82% de los analistas valoran a Grifols por encima de los 10,5 euros https://t.co/TtrSUtMPrC
EL PAÍS Economía@elpais_economia
2 years ago
Grifols se ajusta a los 10,50 euros que ofrece Brookfield mientras los analistas creen que está infravalorada https://t.co/gHO9GPRVZS https://t.co/SBbZFeVWdC

Grifols Faces Brookfield's €6.5 Billion Bid at €10.50 per Share Amid 82% Analyst Skepticism

Sources

Additional media

Similar Stories